These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37343141)

  • 1. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
    Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.
    Zhao SS; Rajasundaram S; Karhunen V; Alam U; Gill D
    Semin Arthritis Rheum; 2022 Oct; 56():152058. PubMed ID: 35839537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease.
    Chen X; Xu C; Hu K; Yang Y; Zhang YJ; Shi HZ; Gu Q; He SM; Zhang C; Wang DD
    Expert Rev Clin Pharmacol; 2023; 16(10):991-998. PubMed ID: 37669251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Goulas A; Polyzos SA
    Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
    Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
    Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
    Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.